The JNMR come in two varieties: Snapshot reports - detailing the current situation of specific products or therapeutic class; and Concept report - providing overview of the market for selected conditions and relevant projections

Interferons

Snapshot report

Abstract: With the latest approval of Betaseron (recombinant beta-1b interferon) of Nihon Schering KK there are already 15 products on the market representing all types of interferon -  alpha (2a, 2b), beta, gamma, natural and recombinant, as the market is estimated to be close to 500 million US dollars annually. Advanced formulations of interferon currently under development are expected to change the market.

Hepatitis Market

Concept report

Abstract: Effective November 1, 2000 the Japanese Ministry of Health, Labor and Welfare created a special "Hepatitis Task Force". The prime objective of the joint task force is to generate policy and practical measures to counteract the growing number of HBV (1 million) and HCV (2 million) cases in Japan, and the highest in the world mortality rate of liver cancer. One of the main implications of the new policy will be the approval of new and advanced therapies still not available in Japan.

Gene and Antisense Therapy

Concept report

Abstract: Effective November 1, 2000 the Japanese Ministry of Health, Labor and Welfare created a special "Hepatitis Task Force". The prime objective of the joint task force is to generate policy and practical measures to counteract the growing number of HBV (1 million) and HCV (2 million) cases in Japan, and the highest in the world mortality rate of liver cancer. One of the main implications of the new policy will be the approval of new and advanced therapies still not available in Japan.

Pancreatic Cancer

Snapshot report

Abstract: For the past twenty years the malignant neoplasia have been the leading cause of death in Japan, and with 17,000 cases annually the pancreatic cancer is the fifth leading cause of cancer death. The classification of pancreatic tumors adopted in Japan differs from UICC system and along with comprehensive surgical approaches creates a significant market opportunities.

Quinolones Development

Concept report

Abstract: As a world leader in the field of the antibacterial therapeutics, a number of new quinolones (including fluoroquinolones) are under development by Japanese pharmaceutical companies. Opportunities for licensing and overseas marketing are reviewed.

Asthma and Allergic Rhinitis Therapies

Concept report

Abstract: Specifics of the comprehensive guidelines by the professional medical societies and the authorities (Japanese Ministry of Health, Labor and Welfare) are aligned with the size and diversity of the market for pediatric asthma therapies and the various treatments of allergic rhinitis.

Statins

Snapshot report

Abstract: Japan is the originator of one of the first and most successful statins - Mevalotin (Pravacol). Concise summaries of data on Prevalence of hyperlipidemia, classes, market and approved indications, reimbursement prices, patent expiration dates and new pipeline of lipid-controlling products.

Migraine and Headache

Concept report

Abstract: Recent simultaneous launch of two major products for treatment of migraine - Imigran (Sumatriptan succinate) Tablets 50 mg by GlaxoSmithKline KK and Zomig (Zolmitriptan) Tablets 2.5 mg by AstraZeneca KK signify the potential of the Japanese headache market. Around 8.4 milion people in Japan are estimated to suffer from migraine or other forms of headache.

Multiple Sclerosis

Concept report

Abstract: A genetical recombination of Interferon beta-1b was designated in Japan as an orphan drug for the treatment of multiple sclerosis in July 1994. The Manufacture and Import Approval for the product under the tradename Betaferon® was granted to Nihon Schering KK in September 2000. Japan is the only region where Betaferon as s.c. injections has been approved for all forms of MS, including relapsing-remitting and secondary-progressive. The development of other products such as Avonex® of Biogen is also reviewed.

Schizophrenia

Concept report

Recent changes in terminology, increased public awareness of the disease and approval of several drug for treatment of schizophrenia profoundly changed the market reflecting the evolvement of market for all major psychiatric disorders.

Insomnia

Concept report

Insomnia and its forms - similarly to all other conditions and disorders related to the mental activities, are difficult to approach and study in Japan. Cultural layers, controversies and still poorly understood patterns in the patients behavior all contribute to making the research on insomnia one of the most  complicated projects in medical and pharmaceutical market research.

Vaccines in Japan

Snapshot report

World-wide treat of newly emerging contagious diseases drew the attention of both public health regulators and vaccine developers to advanced techniques in vaccine manufacturing. Prospects of the vaccine market in Japan are evaluated and the particular regulatory requirements described.